PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGadobutrol
Gadobutrol
Gadavist, Gadobutrol (gadobutrol) is a small molecule pharmaceutical. Gadobutrol was first approved as Gadavist on 2011-03-14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Gadavist, Gadobutrol
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadobutrol
Tradename
Company
Number
Date
Products
GADAVISTBayerN-201277 RX2011-03-14
6 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
gadavistNew Drug Application2025-03-05
gadobutrolANDA2025-04-17
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
GADOBUTROL, GADOBUTROL, HENGRUI PHARMA
2024-04-29CGT
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08C: Magnetic resonance imaging contrast media
— V08CA: Paramagnetic contrast media
— V08CA09: Gadobutrol
HCPCS
Code
Description
A9585
Injection, gadobutrol, 0.1 ml
Clinical
Clinical Trials
106 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Magnetic resonance imagingD008279——2121612
Brain neoplasmsD001932EFO_0003833C71—11147
Breast neoplasmsD001943EFO_0003869C50——2136
FibrosisD005355——1——124
Hepatocellular carcinomaD006528—C22.0———134
Liver neoplasmsD008113EFO_1001513C22.0———134
AtherosclerosisD050197EFO_0003914I25.1———123
Liver cirrhosisD008103EFO_0001422K74.0———123
Peripheral arterial diseaseD058729EFO_0004265————2—2
Peripheral vascular diseasesD016491EFO_0003875I73.9———2—2
Show 11 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324—I25.1——2—68
Myocardial ischemiaD017202EFO_1001375I20-I25——2—46
Neoplasm metastasisD009362EFO_0009708——21—25
Central nervous system diseasesD002493—G96.9—14——5
Nervous system diseasesD009422—G00-G99——3——3
Coronary diseaseD003327————2—13
AdenocarcinomaD000230———11——2
Diagnostic imagingD003952————2——2
Vascular diseasesD014652EFO_0004264I77——1——1
Renal artery obstructionD012078EFO_1001150N28.0——1——1
Show 1 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80—2——68
Myocardial infarctionD009203EFO_0000612I21—1——34
InfarctionD007238EFO_0009463——1——34
Prostatic neoplasmsD011471—C61—2———2
Myocardial perfusion imagingD055414———1——12
Spinal cord diseasesD013118—G95.9—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_0000515—1———23
Heart failureD006333EFO_0003144I501———23
InflammationD007249MP_0001845—1———12
Uterine cervical neoplasmsD002583——1————1
Rheumatoid arthritisD001172EFO_0000685M06.91————1
ArthritisD001168EFO_0005856M05-M141————1
Urinary bladder neoplasmsD001749—C671————1
Pulmonary edemaD011654EFO_1001134J811————1
Female genital neoplasmsD005833——1————1
Interstitial cystitisD018856EFO_1000869N30.11————1
Show 1 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F03————33
Multiple sclerosisD009103EFO_0003885G35————33
SclerosisD012598——————33
Heart diseasesD006331EFO_0003777I51.9————33
CardiomyopathiesD009202EFO_0000318I42————33
Pancreatic neoplasmsD010190EFO_0003860C25————22
LymphomaD008223—C85.9————22
LymphedemaD008209—Q82.0————22
Sleep apnea syndromesD012891EFO_0003877G47.3————22
Cognitive dysfunctionD060825—G31.84————22
Show 70 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGadobutrol
INNgadobutrol
Description
Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
Classification
Small molecule
Drug classgadolinium derivatives (principally for diagnostic use)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID770691-21-9
RxCUI—
ChEMBL IDCHEMBL2218860
ChEBI ID—
PubChem CID72057
DrugBankDB06703
UNII ID1BJ477IO2L (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,573 documents
View more details
Safety
Black-box Warning
Black-box warning for: Gadavist, Gadobutrol
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
5,290 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use